• Consensus Rating: Moderate Buy
  • Consensus Price Target: $120.43
  • Forecasted Upside: 69.43%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$71.08
▼ -1.68 (-2.31%)

This chart shows the closing price for CNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

Analyst Price Target is $120.43
▲ +69.43% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $120.43, with a high forecast of $141.00 and a low forecast of $98.00. The average price target represents a 69.43% upside from the last price of $71.08.

This chart shows the closing price for CNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in CONMED. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$130.00 ➝ $100.00Low
2/1/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$135.00 ➝ $115.00Low
2/1/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$107.00 ➝ $98.00Low
2/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$119.00 ➝ $129.00Low
10/27/2023Piper SandlerLower TargetOverweight ➝ Overweight$145.00 ➝ $130.00Low
10/26/2023Stifel NicolausLower TargetBuy ➝ Buy$136.00 ➝ $120.00Low
10/26/2023Needham & Company LLCLower TargetBuy ➝ Buy$140.00 ➝ $119.00Low
10/26/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$123.00 ➝ $107.00Low
7/27/2023Piper SandlerBoost Target$128.00 ➝ $145.00Low
7/27/2023KeyCorpBoost TargetOverweight$131.00 ➝ $141.00Low
7/24/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$139.00Low
5/22/2023CL KingInitiated CoverageBuy$140.00Low
4/27/2023Stifel NicolausBoost Target$118.00 ➝ $130.00Low
4/27/2023Needham & Company LLCBoost Target$122.00 ➝ $135.00Low
4/27/2023Wells Fargo & CompanyBoost Target$96.00 ➝ $119.00Low
4/27/2023Piper SandlerBoost Target$118.00 ➝ $128.00Low
3/21/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$96.00Low
2/3/2023Needham & Company LLCBoost TargetBuy$106.00 ➝ $122.00Low
2/3/2023Piper SandlerBoost TargetOverweight$108.00 ➝ $118.00Low
11/15/2022Needham & Company LLCBoost TargetBuy$90.00 ➝ $106.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/22/2023
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/21/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 16 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/20/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
CONMED logo
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Read More

Today's Range

Now: $71.08
Low: $70.57
High: $72.79

50 Day Range

MA: $79.92
Low: $71.08
High: $87.76

52 Week Range

Now: $71.08
Low: $70.57
High: $138.47

Volume

620,019 shs

Average Volume

555,047 shs

Market Capitalization

$2.19 billion

P/E Ratio

34.84

Dividend Yield

1.03%

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: CL King, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

7 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $120.43, suggesting a possible upside of 69.4%. KeyCorp has the highest price target set, predicting CNMD will reach $141.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $98.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CNMD.

What other companies compete with CONMED?

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is (727) 392-6464. The official website for CONMED is www.conmed.com. Learn More about contacing CONMED investor relations.